The Mid-trimester Genetic Ultrasound: Past, Present and Future  by Chou, Ching-Yu et al.
143©Elsevier & CTSUM. All rights reserved. J Med Ultrasound 2009 • Vol 17 • No 3
R E V I E W
A R T I C L E
Received: May 15, 2008 Accepted: May 21, 2008
1Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan, 2Department of
Obstetrics and Gynecology, Far Eastern Memorial Hospital, Taiwan, 3Department of Obstetrics and
Gynecology, Cathay General Hospital Shinchu branch, Shinchu, Taiwan, 4School of Medicine, Fu Jen
Catholic University, Taiwan, 5College of Medicine, Taipei Medical University, Taiwan.
*Address correspondence to: Ming-Song Tsai, Prenatal Diagnosis Center, Department of Obstetrics and
Gynecology, Cathay General Hospital, Taipei, Taiwan. E-mail: mstsai@cgh.org.tw
The Mid-trimester Genetic Ultrasound: 
Past, Present and Future
Ching-Yu Chou1, Fu-Shiang Peng2, Fa-Kung Lee3, and Ming-Song Tsai1,4,5*
Down syndrome is the most frequent disease of mental retardation thus many tests have
been developed for its prenatal screening. Among these tests, the mid-trimester genetic
ultrasound examination which assesses enormous soft markers has proceeded for more
than 15 years. Although there is still a debate on the efficiency of the mid-trimester
genetic ultrasound, many sonographers still pay much attention to these soft makers.
One of the reasons is that as maternal age increase, there are more and more pregnant
women over 35 years old and they are suggested to receive an invasive mid-trimester
amniocentesis. However, some of them decline to have an invasive procedure and look
for a noninvasive screening. With advances in the wide acceptance of first-trimester and
second trimester Down syndrome screening, pregnant women with intermediate risk
hesitate in deciding whether they should take the risk of abortion and receive further
amniocentesis. Many expect other non-invasive methods in evaluating their risk of Down
syndrome. In this article, we review the research of all the mid-trimester soft markers
including nuchal thickness, the choroid plexus, hypoplasia of the nasal bone, echogenic
cardiac focus, echogenic bowel, pyelectesis and shorter femurs or humerus. We also
review the history of genetic ultrasound and its efficiency. As more and more non-invasive
tests for Down syndrome are established, we compare the use of the genetic ultrasound
and other maternal serum marker tests, alone and in combination. The future and per-
spectives of mid-trimester genetic ultrasound examination are discussed. Sonography
examination is still one of the most important non-invasive methods for screening Down
syndrome. With more understanding of mid-trimester genetic ultrasound, we can
improve the detection rate of Down syndrome and decrease unnecessary invasive proce-
dures such as chorionic villi samplings and amniocentesises. It may also give more assur-
ance and decrease the anxiety of high risk women older than 35 years old or those told
they have an intermediate risk after receiving first trimester and second trimester Down
syndrome screenings.
■ J Med Ultrasound 2009;17(3):143–156 ■
Introduction
Down syndrome is the most frequent cause of
mental retardation. In addition to mental retarda-
tion, most of Down syndrome affected patients also
suffer from congenital heart disease, hearing loss,
leukemia and Alzheimer’s disease [1]. On average,
raising a Down syndrome affected newborn costs
around US$612,150 in the United States [2].
Having a child newly diagnosed as having Down
syndrome impacts siblings and the family psycho-
logically as well as economically [1]. Down syndrome
was known to be caused by an extra chromosome
21, trisomy 21, which occurs with increasing mater-
nal age. Thus, advanced age pregnant women
who were 35 years or older have routinely under-
gone invasive procedures for cytogenetic diagnosis
since 1970 [3]. However, 70% of Down syndrome
can not be detected using maternal age alone as 
a screening strategy [4]. Also, there are more and
more pregnant women above 35 years old and the
invasive procedure related abortions would in-
crease enormously if all pregnant women who are
older than 35 years old receive invasive testing.
Nowadays, more and more advanced age women
search for second non-invasive tests rather than
receive routine amniocentesis or chorionic villi sam-
plings. Among the non-invasive tests, genetic ultra-
sound examinations attract attention of numerous
researchers.
Since 1992, multiple serum markers including
serum alpha fetoprotein (AFP), free β-human
chorionic gonadotropin (free β-hCG), unconju-
gated estriol (uE3), inhibib A and pregnancy asso-
ciated plasma protein A (PAPP-A) were developed
for Down syndrome screening [4]. The detection
rate of Down syndrome has improved to 80–90%
in the first trimester Down syndrome screening
and the second trimester quadruple test [5].
Although these tests much decrease the false posi-
tive rate and thus reduce invasive procedure
related abortions compared to the strategy using
maternal age alone as a criteria, the results of these
tests confuse pregnant women with an intermedi-
ate risk. Their risk is between 1/270 and 1/1,000.
Usually, they are advised to accept an intermediate
risk and hesitate in deciding whether they should
receive further amniocentesis and take the risk of
an amniocentesis induced abortion. Some of these
patients search for a different and independent
method to reevaluate their intermediate risk.
Genetic ultrasound reveals its importance in these
circumstances. In this article, we review the
researches of all mid-trimester soft markers includ-
ing nuchal thickness, choroid plexus, hypoplasia of
nasal bone, echogenic cardiac focus, echogenic
bowel, pyelectesis and shorter femurs or humerus.
We also review the history of genetic ultrasound
and its efficiency.
Multiple Soft Aneuploidy Markers
Aneuploidy markers are usually classified into major
markers and minor markers (soft markers). The
major markers mean the presence of a major fetal
anomaly in the brain, heart, lung, gastrointestinal
tract, genital organs or the four limbs. Newborns
with these major anomalies need further surgery
even when their karyotype is normal. These major
markers include holoprosencephalies, agenesis of
corpuscallosum (ACC), facial clefts, radial clubhand,
arthrogyposis, congenital diaphragmatic hernia,
congenital heart disease, omphaolocele and duo-
denal atresia. Theses major markers and their asso-
ciation with aneuploidy are listed in Table 1.
The soft markers are usually non-specific and
maybe transient. They did not threaten the health
of neonates. However, these findings imply in-
creased risk of chromosome anomalies. The role of
soft markers in screening Down syndrome is also
controversial. We list all previous reports of these
soft markers and define their criteria separately in
Table 2.
Nuchal Fold Thickness
In 1985, Benacerraf et al reported that nuchal fold
measurement is a sensitive and specific sonographic
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Table 1. Major anomalies and their association with aneuploidy
Anormaly Incidence 
Percentage associated 
Aneuploidy
with aneuploidy
Holoprosencephalies – – Trisomy 13
Agenesis of corpus callosum 0.3–0.7% – Trisomy 8, 13, 18
Facial clefts 0.14% – Trisomy 10, 13, 18, 22, 9
Radial clubhand – – Trisomy 18 and 21
Arthrogryposis 3/10,000 59% (26/52) Trisomy 18
Congenital diaphragmatic hernia 1/2,200 10.5% Trisomy 18
Congenital heart disease 75/1,000 15–50% Trisomy 13, 18, 21 and 
triploidy
Omphaolocele 0.74–3.9/10,000 30–40% Trisomy 13, 18 and 21
Duodenal atresia 1:5,000–10,000 24–35% Triosmy 21
Table 2. Soft markers and their association with aneuploidy
Soft markers
Prevalence in Percentage of 
Reference
normal population Down syndrome
Nuchal thickness (> 6 mm) 0 [6] 12% (6/19) Odibo, 2008 [11]
0.5% (136/24,325) 34.1% (85/249) Vintzileos, 1995 [87]*
Nasal hypoplasia (< 0.75 MoM) 0.9% (25/2,868) 37% (54/146) Sonek, 2006 [20]
2.9% (74/2,515) 85.7% (18/21) Gianferrari, 2007 [23]
Short femur length 5% (616/11,873) 31% (151/483) Vintzileos, 1995 [87]*
(observed/expected < 0.91)
Short femur length 4.5% (378/8,385) 33% (54/165) Vintzileos, 1995 [87]*
(observed/expected < 0.9)
Echogenic cardiac focus 240/– 0% (0/27) Ouzounian, 2007 [54]
1.5% (359/23,346) 14/– Goncalves, 2006 [55]
4.7% (62/1,312) 18% (4/22) Bromley, 1995 [50]
4.6% (147/3,192) 30% (16/53) Winter, 2000 [49]
2.3% (260/11,135) 20% (5/25) Anderson, 2003 [52]
3.9% (311/10,769) 7.1% (1/14) Lamont, 2004 [53]
(–/39,230)† 22% (–/130)† Sotiriadis, 2003 [56]*
Hyperechoic bowel 0.6% (50/8,680) 12.5% (6/48) Bromley, 1994 [88]
Hypoplasia of the middle 18% (–/1,024) 75% (6/8) Benacerraf, 1990 [65]
phalanx of the fifth digit
3.1% (13/420) 15.4% (2/13) Vintzileos, 1996 [66]
Sandal gap 1% (4/42) 25% (1/4) Vintzileos, 1996 [66]
Pelviectasis 4.7% (20/420) 20% (4/20) Vintzileos, 1996 [66]
2.7% (203/7,393) 25% (11/44) Benacerraf, 1990 [46]
*Meta-analysis study that review all literature in the MedLine; †Isolated finding of echogenic intracardiac focus.
finding for detecting Down syndrome in the sec-
ond trimester [6–9]. Measurement of nuchal fold
thickness was taken by a modified transverse view
of the fetal head [9]. Nuchal fold thickness was
measured from the outer edge of the occipital
bone to the outer edge of the skin fold [9]. The
width of the nuchal fold in a normal fetus was con-
sistently between 1 and 5 mm regardless of gesta-
tional age (15 to 20 weeks) [6], while 12–75%
[9–11] of Down syndrome cases show a nuchal
fold thickness more than 6 mm. Although the de-
tection rate (sensitivity) of this marker fails to reach
50% (4% in isolated increased nuchal thickness
and 26% in cases with structural anormaly) in the
meta-analysis of previous studies, this soft marker
is still thought to be valuable due to its high speci-
ficity (99%) [12]. It is interesting that this soft
marker could be transient and may resolve at the
second trimester [13]. Thus, the resolving nuchal
fold in second trimester fetuses is not necessarily
reassuring [14].
Nasal Hypoplasia
Sonek and Nicolaides first described absence or
hypoplasia of the nasal bone in three mid-trimester
fetuses with prenataly diagnosed Down syndrome
[15]. They suggested a slightly parasagittal view to
measure the length of fetal nasal bone, at the opti-
mal angles of 45 degrees or 135 degrees. If this
angle is less than 45 degrees or greater than 135
degrees, the nasal bone may artificially appear to be
absent [15]. As the angle of insonation approaches
90 degrees, the edges of the nasal bone may be-
come difficult to delineate precisely because of echo
scatter, and the nasal bone measurement may there-
fore become artificially large [15]. Figure 1 shows
the face profile of a fetus with prenataly diagnosed
Down syndrome in our hospital. A slightly para-
sagittal view reveals absence of the nasal bone and
this characteristic changes the appearance of the
fetal face profile.
After this report, a lot of research was con-
ducted to evaluate efficiency of the nasal bone
hypoplasia for screening Down syndrome [11,
16–31]. The measurement of the nasal bone was
performed in the first trimester and the second
trimester. Absence of the fetal nasal bone in the
first trimester was proved to improve the detection
rate of Down syndrome if nuchal transluceny
thickness and serum biochemistry (PAPP-A and
free b-hCG) were combined to assess risk [26].
However, this marker is still thought to be second-
ary and only should be evaluated by sufficient ade-
quately trained sonographer [26]. In the second
trimester, four different methods to define nasal
hypoplasia have been used in previous studies. (1)
A measurement below the 2.5th, 5th, or 10th per-
centile of the normal range for gestation [32–34];
(2) A measurement below a fixed cutoff of 2.5 mm
or 3 mm [16]; and (3) A ratio above a specific crite-
ria in the ratio of the biparietal diameter to nasal
bone length ratio [35, 36]. (4) Evaluating nasal
bone length by multiples of the median (MoM)
[23,25]. Recently, Odibo et al reported that defin-
ing nasal bone hypopasia in the second trimester
as less than 0.75 MoM has better specificity [25].
After this report, evaluating nasal bone length by
MoM and taking account of ethnicity and gesta-
tional ages are most widely accepted in many 
centers [28,31].
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Fig. 1. The face profile of a fetus with prenataly diagnosed
Down syndrome. Slightly parasagittal view reveals an absence
of the nasal bone (asterisk) and this characteristic changes the
appearance of fetal face profile.
Hyperechoic Bowel
Hyperechoic bowel was defined as an increase of
the echogenicity of the fetal bowel to that of equal
to bone [37]. This finding is associated with several
conditions including aneuploidy, infection, growth
restriction, cystic fibrosis and Rhesus sensitization
[38–45]. This may be due to bowel hypotonia with
excessive desiccation of the meconiusm such as in
fetuses with Down syndrome, viscid meconium
such as intrauterine growth restriction, cystic fibro-
sis, or fetal swallowing of blood in the amniotic
fluid and external compression of the bowel by a
tumor or ascites [39]. Because the echogenicity of
the fetal bowel can be subjective and may vary
according to the ultrasound machine and the fre-
quency of the transducer used, and the majority of
fetuses with hyperechoic bowel have a normal out-
come [37], it is controversial to use this marker as 
a tool to screen Down syndrome. In the Strocker 
et al’s study, only 8% (5/62) of fetuses with iso-
lated hyperechoic bowel had aneuploidy.
Renal Pyelectasis
Renal pyelectasis was defined by Beacerraf et al as
an anteroposterior diameter of the fetal renal pelvis
of ≥ 4 mm at 16–20 weeks, ≥ 5 mm at 20–30 weeks
or ≥ 7 mm at 30–40 weeks gestation (Fig. 2) [46].
In their study, 25% of affected fetuses had renal
pyelectasis compared with 2% to 3% of unaffected
fetuses [46]. In previous publications, many authors
found that the likelihood ratios of renal pyelectasis
for Down syndrome is around 1.5 to 1.9 [12,47].
However, just like other soft markers, isolated renal
pyelectasis was found frequently among normal
fetuses.
Echogenic Cardiac Focus
In 1994, Brown et al described left ventricular echo-
genic focus in the fetal heart and one of the three
fetuses had trisomy 21 [48]. These intracardiac
echogenic foci or “golf balls” represent mineraliza-
tion within the fetal papillary muscle [48]. Under
sonographic examination an echogenic intracra-
diac focus is a bright area as bright as bone gener-
ally in the left ventricle but occasionally bilateral or
right-sided, located just below the mitral or tricus-
pid valves [13]. After this report, many studies have
been reported including those that were positive
[49,50] and those that has no association [51,52]
with trisomy 21. Although many authors recognized
this finding as a normal variant [53] and found no
difference when these neonates are follow up 3
months later [51,52,54], many authors still find
that the incidence of this marker among trisomy
21 cases is higher than in normal populations
[49,50,55]. These studies are listed in the Table 2.
Among these studies, Sotiriadis et al performed a
meta-analysis including 11 studies published from
1995 to 2001 [56]. There were totally 39,230 nor-
mal cases and 130 cases of Down syndrome in the
isolated settings in which echogenic intracardiac
focus was an isolated finding [56]. The weighted
sensitivity and specificity for isolated finding was
0.22 (95% confidence interval, 0.1–0.33) and
0.959 (95% confidence interval, 0.91–0.982) [56].
Based on the random effects estimates, the positive
likelihood ratio was 5.4 in the “isolated” setting
and the negative likelihood ratio value was 0.81
[56]. Thus the author concluded that echogenic
Genetic Ultrasound: Past, Present, and Future
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Fig. 2. Renal pyelectasis was defined by Beacerraf et al as an
anteroposterior diameter of the fetal renal pelvis of ≥ 4 mm at
16–20 weeks and ≥ 5 mm at 20–30 weeks.
intracardiac echogenic foci have modest diagnostic
performance [56].
However, Caughey et al reported that using
echogenic intracardiac focus as a screening tool in
low risk populations would lead to a large number
of amniocenteses and miscarriages to identify a
small number of Down syndrome fetuses based on
their model [57]. This marker seems to be noted
more frequently in the normal Asian populations
[58,59]. Thus, amniocenteses due to isolated ultra-
sound finding should not be encouraged espe-
cially in the Asian population. However, some
authors found the echogenic intracardiac focus is
associated with cardiac anomalies and suggest
women carrying fetuses with the echogenic in-
tracardiac focus should be offered detailed fetal
echocardiography [55].
Hypoplasia of the Middle Phalanx of
the Fifth Digit (Clinodactyly) and 
Sandal Gap
Hypoplasia of the middle phalanx of the fifth digit
and simian crease were thought to be one of the
characteristics in the Down syndrome hand and 
was noted in 60% of Down syndrome affected
infants (Fig. 3A) [60]. Unlike simian crease which is
difficult to identify, prenatal ultrasound screening of
hypoplasia of the middle phalanx of the fifth digit
was performed by many authors in their genetic
sonogram [61–64]. In the second trimester, a Down
syndrome affected fetus showed hypoplasia or
absence of the middle phalanx of the fifth digit
(Fig. 3B) and the fifth digit also curved abnormally
inward [62]. Benacerraf et al measured the ratio of
the middle phalanx of the fifth digit over the mid-
dle phalanx of the fourth digit [65]. If the cut-off of
ratio was defined as 0.7, 75% (6/8) of Down syn-
drome cases could be detected while 18% (2/13)
of Down syndrome affected fetuses showed this
characteristic [66]. However, it is important to re-
member that the middle phalanx of the fifth digit
was only visualized in 14.3% (2/14) of cases at 
13 weeks, 70.3% (154/219) at 14 weeks, 82.2%
(240/292) at 15 weeks, 97.4% (111/114) at 16
weeks and 100% (43/43) at 17 weeks of gestation
according to Zalel et al’s study [64]. This empha-
sizes the limited role of non-ossification of the 
middle phalanx of the fifth digit as a sonographic
marker of Down syndrome before 17 weeks of ges-
tation [64]. Absence of the middle phalanx of the
fifth digit at 14 weeks may disappear at 20 weeks
(Fig. 4A and 4B).
The sandal gap deformity was first described by
Wilkins et al in 1994 [67,68]. This deformity is 
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Fig. 3. (A) Hypoplasia of the middle phalanx of the fifth digit (asterisk) and a simian crease were thought to be one of the char-
acteristics in the Down syndrome’s hand and was noted in 60% of Down syndrome affected infants. (B) In the second trimester, 
a Down syndrome affected fetus showed hypoplasia or an absence of the middle phalanx of the fifth digit.
a noticeably large separation of the great toe 
and the second toe (Fig. 5). Little research of the
sandal gap was found in the previous study. This
may be due to difficult definition of this deformity
and high false positive rate among the normal
fetuses.
Short Femur and Short Humerus
Since 1987, because children affected with Down
syndrome were noted to have a shorter stature,
the link with a shorter femur and shorter humerus
was studied and proved to be associated with
Down syndrome [69,70]. Locwood et al chose an
upper limit of 1.5 standard deviations above the
mean in the biparietal diameter (BPD)/femur
length ratio [68,69]. While Benaceraf et al calcu-
lated the observed-to-expected femur length ratio
and found an increased risk of Down syndrome 
if the ratio was less than 0.91 [70]. Based on 192
normal fetuses, the expected femur length can be
estimated as (0.9028 × BPD) − 9.3105 [70]. In pre-
vious studies, the detection rate of BPD/femur
ratio for Down syndrome ranged from 18% to
70% with positive screen rate of 2% to 23% [68]
and the detection rate of observed to expected
femur length ratio for Down syndrome ranged
from 12% to 68% with positive screen rate of 2%
to 15% [68]. Conversely, the expected humerus
length was calculated as (0.8492 × BPD) − 7.9404
based on 400 normal fetuses [71]. The detection
rate of Down syndrome by using the criteria of
observed to expected humerus ratio less than 0.9
alone was 50% with a positive screen rate of
6.25% [71]. If a shorter humerus and femur were
both used in combination, Biagiotti et al reported
that the detection rate was 44.4% in 27 cases of
Down syndrome and the positive screen rate could
be decreased to 7.6% [72].
Like the marker of nasal hypoplasia, a shorter
femur and humerus were noted more frequently in
the Asian population [73]. And there were also
reports that the difference of gender influenced
the length of femur and humerus of Down syn-
drome affected fetuses [74].
Genetic Ultrasound: Past, Present, and Future
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Fig. 4. (A) Absence of the middle phalanx of the fifth digit at 14 weeks (B) may disappear at 20 weeks.
Fig. 5. The sandal gap deformity (asterisk) was noted in a
Down syndrome affected fetus. There is a separation of the
great toe from the second toe.
Other Markers
Choroid plexus cysts in the mid-trimester were
thought to be associated with aneuploidy, espe-
cially with trisomy 18 [75]. However, invasive pro-
cedures such as amniocentesis should not be
offered for cases with isolated choroids plexus cysts
because of its low cost-effectiveness [75]. Some
authors suggest estimating the patient’s risk of tri-
somy 18 by multiplying the prior risk (the risk
assigned by serum screening or the age-related
risk if no serum screening done) by the likelihood
ratio of 9 [75,76].
Usually, the normal umbilical cord has one vein
and two arteries, while a fetus with single umbilical
artery has only one artery and one vein (Fig. 6).
There is a well-known association between single
umbilical artery and cytogenetic abnormly, espe-
cially trisomy 18 [77]. Other abnormal karyotypes
include Turner syndrome, trisomy 13 and triploidy
[77]. Although no obvious association with Down
syndrome was reported, some author finds it is
associated with congenital anormalies including
the heart, the gastrointestinal system and the cen-
tral nervous system. The incidence for cytogenetic
abnormalities among fetuses demonstrating single
umbilical artery has been reported at 17%, with
nearly one half of these fetuses having major
anomalies [77].
Combination of Multiple Soft Markers
in the Mid-trimester Genetic Sonogram
As more and more soft makers are proved to be
associated with trisomy 21, many authors are try-
ing to find an effective strategy to combine all of
the useful soft makers. The goal of this research
was to increase the detection rate of Down syn-
drome affected fetuses and decrease the false pos-
itive rate as much as possible. Since 1992, the
outcomes of this research was highly variable and
the sensitivity ranging from 50% to 93% (Table 3)
[78–86].
This is because the studied subject, number of
soft markers, definition of soft markers, combined
serum markers, ethnicity, trained sonographers,
samples sizes and method of analysis were all dif-
ferent. Also, it is difficult to obtain a meta-analysis
which combines all the data from these different
groups. Before 1998, all studied subjects were high
risk pregnancies including those with an advanced
maternal age, high risk of serum double test or
triple test, or previous affected offspring. For these
cases a, sonographic score index system which was
developed by Benacerraf et al was the most popu-
lar [78]. However, most of these studies have a
high false positive rate which is over 10%. In 1998,
Nyberg et al developed a different way to combine
these soft markers [84]. They used age-adjusted
ultrasound risk assessment (AAURA) which assesses
the individual risk for fetal Down’s syndrome based
on maternal age and second-trimester ultrasound
findings. All soft markers were given an individual
likelihood ratio (LR) such as structural abnormality
(LR 25), nuchal thickening (LR 18.6), echogenic
bowel (LR 5.5), shortened humerus (LR 2.5), short-
ened femur (LR 2.2), echogenic intracardiac focus
(LR 2), and renal pyelectasis (LR 1.6) [84]. The
advantage of this method is that multiple markers
including maternal age, serum markers and sono-
graphic soft markers can be taken into account
and give an individual risk for different patients.
This risk can be weighed against the risk of invasive
procedures such as amniocentesis and the patient
can make a decision more easily. Unfortunately,
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Fig. 6. Usually, the normal umbilical cord has one vein and
two arteries, while a fetus with a single umbilical artery has
only one artery and one vein.
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the detection rate of this method did not appear
superior to the sonographic scoring index system
(Table 3).
Evidence has showed that first trimester Down
syndrome screening which includes measurement
of nuchal thickness, pregnancy-associated plasma
protein-A(PAPP-A) and free beta-human chorionic
gonadotropin (free β-hCG), can reach a high de-
tection rate of 85% with a low false positive rate of
5% [5]. Because of a lack of an adequate facility
and trained sonographers, some areas use a second
trimester quadruple test which includes measure-
ments of alpha-fetoprotein, total human chorionic
gonadotropin, unconjugated estriol, and inhibin A,
and can reach a similar detection rate and false
positive rate compared to first trimester Down syn-
drome screening [5]. We suggest that the second
trimester genetic sonogram cannot replace Down
syndrome screening due to a lack of large trials and
a stable detection rate of previous studies. How-
ever, there are more and more researchers using
genetic sonogram as the second line of Down syn-
drome screening, especially when women with high
risk pregnancies decline invasive procedures and
search for non-invasive methods. In some studies,
although a genetic sonogram cannot reach high
detection rates, it can decrease the risk of Down
syndrome if all soft makers can not been seen.
Future Perspectives
At present, it is hard to improve upon the detection
rates of mid-trimester genetic sonogram for Down
syndrome among the low risk pregnancies and this
possibly leads to more invasive procedures inducing
abortion due to high false positive rates. More evi-
dence is still needed to prove that a second trimester
genetic sonogram can decrease unnecessary inva-
sive procedures among high risk pregnancies and
give greater assurance to women with high risk
pregnancies. Before the genetic sonogram can be
accepted worldwide, unifying the definition of soft
makers, auditing adequate sonographers and giving
adequate genetic counseling is very important.
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